Medicare Part D coverage · 0.2 · RxCUI 2663904
0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita]
Per the CMS 2026 Part D formulary file, 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] is covered by 142 Medicare Part D plans (2.8% of enrollable products), averaging Tier 4.3, with prior authorization required on 66.7% of covering formularies.
- 2.8%
- Plan coverage
- 142
- Plans covering
- T4.3
- Avg tier
- 66.7%
- Prior auth required
What the CMS Formulary Data Shows for 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita]
Per the CMS 2026 Part D formulary file, 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] (RxNorm concept RXCUI 2663904, generic name 0.2) appears on 6 distinct formulary files spanning 142 Medicare Part D plan offerings - 2.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 5, with a cross-plan average of Tier 4.3.
Real-world access to 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] depends on utilization management as much as tier placement: 66.7% of covering formularies require prior authorization. 0% require step therapy. 50% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] today.
Coverage Details
- Formularies covering
- 6
- Plans covering
- 142
- Coverage rate
- 2.8%
- Tier range
- Tier 3 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 66.7% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 50% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] covered by Medicare Part D?
Yes, 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] is covered by 142 Medicare Part D plans (2.8% of all Part D formularies).
What tier is 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] on Medicare Part D plans?
0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] averages Tier 4.3 across Part D plans, ranging from Tier 3 to Tier 5.
Does 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita] require prior authorization?
66.7% of Part D formularies require prior authorization for 0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe [Amjevita]. Step therapy: 0%. Quantity limits: 50%.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 1 ML leuprolide acetate 7.5 MG/ML Prefilled Syringe [Lupron] T4.3
- 3 ML icatibant 10 MG/ML Prefilled Syringe [Sajazir] T4.3
- omadacycline 100 MG Injection [Nuzyra] T4.3
- sacrosidase 8500 UNT/ML Oral Solution [Sucraid] T4.3
- deflazacort 22.75 MG/ML Oral Suspension T4.3
- {28 (alpelisib 125 MG Oral Tablet [Vijoice]) } Pack [Vijoice 125 MG 28 Day] T4.3
Similar prior-authorization rate
- meperidine hydrochloride 10 MG/ML Oral Solution 66.7% PA
- tretinoin 0.25 MG/ML Topical Cream [Retin-A] 66.7% PA
- 1 ML meperidine hydrochloride 25 MG/ML Injection 66.7% PA
- tazarotene 0.5 MG/ML Topical Cream [Tazorac] 66.7% PA
- Modified 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet 66.7% PA
- 0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor] 66.7% PA